Abstract
Introduction: Despite data showing reductions in risk of death and heart failure hospitalization in heart failure patients with reduced ejection fraction (HFrEF), sacubitril/valsartan (SV) and mineralocorticoid-receptor antagonist (MRA) adoption rates have remained low. We hypothesized that instituting a quality initiative (QI) that prospectively identified SV/MRA candidacy in HFrEF patients and tied successful use of MRA/SV in eligible patients to total health system compensation would improve utilization rates. Methods: A HFrEF QI was implemented whereby a portion of a large outpatient cardiology practice’s total compensation by the health system was tied to successful SV and MRA use in HFrEF patients (EF<40%) with NYHA class II-IV symptoms. Quality metric goals that triggered maximum reimbursement were set at >25% SV use and >60% MRA use in eligible HFrEF patients, given the low rates of appropriate SV and MRA use nationally. Following QI introduction, patients with the above eligibility criteria were prospectively identified over one year. Providers were sent daily e-mails notifying them of eligible patients that day, and during the patient visit were prompted to complete a form, documenting use of SV, MRA, and/or any contraindications to their use including blood pressure, renal function, potassium level, ACE/ARB intolerance, or financial obstacles. To serve as a control arm, data was retrospectively collected on 6 months of consecutive HFrEF patients with the same eligibility criteria prior to QI initiation. Results: Of 1345 retrospectively identified HFrEF patients prior to initiating the QI, 855 (63.5%) and 964 (71.7%) met SV and MRA eligibility criteria. Of these, 324 (37.9%) were prescribed SV, 365 (37.9%) an MRA. Following QI implementation, 3792 patients with HFrEF were prospectively identified, and of these 2550 (67.2%) and 2589 (68.2%) met eligibility criteria for SV and MRA initiation. SV use in eligible patients increased from 37.9% pre-QI, to 72.1% post-QI (p < 0.001). MRA use increased from 37.9% pre-QI to 66.2% post-QI (p < 0.001). Conclusions: A quality initiative linking successful implementation of SV and MRA use in eligible HFrEF patients to physician compensation resulted in a significant increase in SV and MRA adoption rates.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.